BGLC — BioNexus Gene Lab Corp
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2023-07-20.
Performance
Technicals
Others in Healthcare
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-13 | Bin Abdul Hamid Muhammad Azrul Director | Grant or award | 32.3K | — | — |
| 2026-08-13 | Low Jook Yuen Director | Grant or award | 16.1K | — | — |
| 2026-08-13 | Chong Set Fui Chief Financial Officer | Grant or award | 96.8K | — | — |
| 2026-08-13 | Yap Chee Keong Director | Grant or award | 32.3K | — | — |
| 2026-08-13 | Tan Lee Su-Leng Chief Executive Officer | Grant or award | 338.7K | — | — |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| UBS Group AG | 495 | 231 |
| WELLS FARGO & COMPANY/MN | 2 | 1 |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13D | 2026-08-14 | — | on EDGAR ↗ |
| 4 | 2026-08-14 | 2026-08-13 | on EDGAR ↗ |
| 4 | 2026-08-14 | 2026-08-13 | on EDGAR ↗ |
| 4 | 2026-08-14 | 2026-08-13 | on EDGAR ↗ |
| 4 | 2026-08-14 | 2026-08-13 | on EDGAR ↗ |
| 4 | 2026-08-14 | 2026-08-13 | on EDGAR ↗ |
| 10-Q | 2026-08-14 | 2026-06-30 | on EDGAR ↗ |
| 3 | 2026-08-07 | 2025-11-28 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- BioNexus Gene Lab Corp (BGLC) filed form 10-Q · 2026-08-14 · SEC EDGAR
- BioNexus Gene Lab Corp (BGLC) filed form 4 · 2026-08-14 · SEC EDGAR
- BioNexus Gene Lab Corp (BGLC) filed form SCHEDULE 13D · 2026-08-14 · SEC EDGAR
- BioNexus Gene Lab Corp (BGLC) filed form 4 · 2026-08-14 · SEC EDGAR
- BioNexus Gene Lab Corp (BGLC) filed form 4 · 2026-08-14 · SEC EDGAR
- BioNexus Gene Lab Corp (BGLC) filed form 4 · 2026-08-14 · SEC EDGAR
Ask the AI about BGLC
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →